0.00
—
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Infinity Pharmaceuticals
Its shares trade under the ticker INFIQ. It has been listed since 27 July 2000. In the fiscal year to 31 December 2022, it reported revenue of $2.6m and a net loss of $44.4m. At that date it held total assets of $42.2m and shareholders' equity of −$19.1m.
Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2000-07-27. The firm is engaged in the discovery, development and delivery of medicines to treat diseases. The firm develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The firm is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The firm also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 27 Jul 2000
- Employees
- 25
- Website
- infi.com ↗
Leadership
Pay as last reported
- Mr. Seth TaskerChief Executive Officer$1.4m
- Mr. Norman SelbyLead Independent Director$125,815
- Mr. David BeierIndependent Director$85,576
- Dr. Anthony EvninIndependent Director$93,076
- Dr. Richard GaynorIndependent Director$83,076
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 19
- Environment
- 18
- Social
- 21
- Governance
- 18
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Infinity Pharmaceuticals Inc possesses several strengths that contribute to its success and competitive advantage in the industry. These strengths include:
- Infinity Pharmaceuticals Inc has a well-established research and development (R&D) department, which allows them to continuously innovate and develop new drugs and therapies. This helps in staying ahead of competitors and meeting the changing needs of the market.
- The company has a diverse and promising drug pipeline, with several potential candidates in various stages of development. This provides them with the opportunity to secure future revenue streams and expand their product portfolio.
- Infinity Pharmaceuticals Inc has established strategic partnerships with leading pharmaceutical companies, allowing them to leverage the resources, expertise, and distribution networks of their partners. These collaborations enhance their market presence and facilitate the commercialization of their drugs.
Weaknesses
- Despite its strengths, Infinity Pharmaceuticals Inc also faces certain weaknesses that pose challenges to its growth and sustainability. These weaknesses include:
- The company may face constraints in terms of financial resources and funding, which could impact their ability to fully capitalize on research opportunities, expand operations, or effectively compete with larger pharmaceutical companies.
- Infinity Pharmaceuticals Inc's revenue stream heavily relies on a few key products. Any setbacks in the development, approval, or commercial success of these products can significantly impact the company's financial performance.
Opportunities
- Infinity Pharmaceuticals Inc can capitalize on various opportunities to further enhance its market position and achieve sustained growth. These opportunities include:
- As the healthcare industry evolves, there is an increasing demand for innovative therapies and personalized medicine. Infinity Pharmaceuticals Inc can leverage its strong R&D capabilities to develop and commercialize novel treatments that address unmet medical needs.
- The company can explore additional strategic partnerships and collaborations to access new markets, technologies, or research expertise. Such alliances can enable them to accelerate drug development, increase market reach, and diversify their product offerings.
Threats
- Infinity Pharmaceuticals Inc faces certain threats that could hinder its growth and profitability. These threats include:
- The pharmaceutical industry is highly competitive, with numerous companies vying for market share. Infinity Pharmaceuticals Inc faces competition from both established pharmaceutical companies and emerging biotech firms, which may affect their market penetration and pricing power.
- Developing and commercializing pharmaceutical products involves navigating complex regulatory processes and receiving necessary approvals. Any delays or regulatory hurdles can impact product launches and revenue generation for Infinity Pharmaceuticals Inc.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.